An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Andrew DeFrancesco, Chief Executive Officer of SOL Global Investments Corp. (the “Company” or “SOL Global”), announces that on August 18, 2021, he acquired ownership of 330,700 common shares in the capital of SOL Global (the “Common Shares”) on the Canadian Securities Exchange at an average price of CAD$3.5926 per Common Share (the “Market Transaction”) and an additional 300,000 Common Shares from one arm’s length vendor in a private transaction at a price of USD$3.30 per Common Share (the “Private Transaction”, and collectively with the Market Transaction, the “Transactions”). The completion of the Transactions resulted in an increase from approximately 0.97% to approximately 2.18% in Mr. DeFrancesco’s security holding percentage of the issued and outstanding Common Shares on a non-diluted basis. In addition, Mr. DeFrancesco owns 3,112,000 deferred share units (the “DSUs”) and 1,400,000 performance share units (the “PSUs”). The DSUs and PSUs may be settled for Common Shares at the sole discretion of the Company. Assuming that all of the DSUs and PSUs are each settled for one Common Share, Mr. DeFrancesco will own 10% of the issued and outstanding Common Shares on a partially-diluted basis.
“SOL is one of the best stocks in my humble opinion for upside based on our holdings and factoring in the temporary weakness in the US Cannabis sector”, said SOL Global CEO, Mr. DeFrancesco. “My best returns have come from betting on myself and once again I have a Super Star team supporting me”.
Mr. DeFrancesco acquired the securities reported herein for investment purposes. Mr. DeFrancesco may, depending on market and other conditions, increase or decrease his beneficial ownership in the Company’s securities, whether in transactions on the open market, by privately negotiated arrangements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities.
This news release is being issued to comply with National Instrument 62-104 - Take-Over Bids and Issuer Bids and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. An early warning report will be filed and available on SEDAR regarding the Transactions. To obtain more information or to obtain a copy of the early warning report to be filed in respect of this news release, please contact SOL Global at the contact details noted below.
scythian is a pharmaceutical development company currently undertaking pre-clinical testing at the university of miami on a combination drug therapy for the treatment of traumatic brain injury ("tbi") and concussion. tbi happens when there is a major impact to the head or subjected to accelerative forces. it frequently results in both initial damage from the impact itself and significant subsequent damage from inflammation and the body's own immune response. a significant amount of brain injury occurs from the inflammatory and immune response. scythian’s pharmaceutical approach aims to reduce both the inflammation and the immune response by using a combination of two drugs as the acute emergency room or post injury treatment. a broad based u.s. provisional patent application has been filed utilizing drug combinations which affect the endocannabinoid pathway to treat concussions. scythian's second business line is its application to become a licensed producer of medical marijuana in can
